Literature DB >> 34548225

Involvement of the circular RNA/microRNA/glucose-6-phosphate dehydrogenase axis in the pathological mechanism of hepatocellular carcinoma.

Ying Wang1, Xin-Yi Zhou1, Xiang-Yun Lu2, Ke-Da Chen1, Hang-Ping Yao3.   

Abstract

Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related death worldwide with high mortality. The incidence of HCC is increasing in China. Abnormal activation of glucose-6-phosphate dehydrogenase (G6PD) exists in all malignant tumors, including HCC, and is closely related to the development of HCC. In addition, the differential expression of non-coding RNAs is closely related to the development of HCC. This systematic review focuses on the relationship between G6PD, HCC, and non-coding RNA, which form the basis for the circRNA/miRNA/G6PD axis in HCC. The circular RNA (circRNA)/microRNA (miRNA)/G6PD axis is involved in development of HCC. We proposed that non-coding RNA molecules of the circRNA/miRNA/G6PD axis may be novel biomarkers for the pathological diagnosis, prognosis, and targeted therapy of HCC.
Copyright © 2021. Published by Elsevier B.V.

Entities:  

Keywords:  Glucose-6-phosphate dehydrogenase; Hepatocellular carcinoma; Non-coding RNA

Mesh:

Substances:

Year:  2021        PMID: 34548225     DOI: 10.1016/j.hbpd.2021.08.013

Source DB:  PubMed          Journal:  Hepatobiliary Pancreat Dis Int


  2 in total

1.  LncRNA n339260 functions in hepatocellular carcinoma progression via regulation of miRNA30e-5p/TP53INP1 expression.

Authors:  Tieju Liu; Jing Mo; Shihan Liao; Xiaoyu Bai; Yanlei Li; Yanhui Zhang; Danfang Zhang; Runfen Cheng; Nan Zhao; Na Che; Yuhong Guo; Xueyi Dong; Xiulan Zhao
Journal:  J Gastroenterol       Date:  2022-07-08       Impact factor: 6.772

2.  Construction of a competing endogenous RNA network to analyse glucose-6-phosphate dehydrogenase dysregulation in hepatocellular carcinoma.

Authors:  Pengyu Wang; Xitong Yang; Dan Liu; Yunhui Yang; Yuanyuan Zhang; Guangming Wang
Journal:  Biosci Rep       Date:  2022-06-30       Impact factor: 3.976

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.